Summary : The FDA today approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.…
Merck & Co
-
-
Bristol Myers SquibbCompaniesMerck & CoMerger / Acquisition
BMS and Merck Buy Big Into Amphista’s Protein Degradation Platform with 2.3 Billion Collab
by adminby adminSummary : Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with both inking partnerships with Amphista Therapeutics…
-
CompaniesMerck & CoMerger / Acquisition
Merck & Co pens $340m pain drug deal with KCL and Wellcome
by adminby adminSummary Merck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new class of painkillers…
-
AstraZenecaCompaniesMerck & CoRegulatoryU.S FDA
AZ, Merck get FDA okay for Lynparza as adjuvant breast cancer therapy
by adminby adminSummary : The FDA has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending…
-
CompaniesJapanMerck & CoOthers
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
by adminby adminSummary : MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare…
-
CompaniesMerck & Co
European Commission Approves Merck’s Pneumococcal vaccine Vaxneuvance (Pneumococcal 15-Valent Conjugate Vaccine) for Individuals 18 Years of Age and Older
by adminby adminSynopsis : – The administration of the vaccine in accordance with the official recommendation can effectively prevent invasive disease and pneumonia caused…
-
CompaniesMerck & Co
Merck’s Keytruda Gets EU Approval for Treatment of Triple-Negative Breast Cancer.
by adminby adminThe European Commission has cleared Keytruda (Pembrolizumab) in combination with chemotherapy as a first-line treatment for locally recurrent, unresectable or metastatic TNBC…